Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis GilesInstitute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, USAAbstract: Chronic myeloid leukemia (CML) is the consequence of a single balanced...

Full description

Bibliographic Details
Main Authors:	Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis Giles
Format:	Article
Language:	English
Published:	Dove Medical Press 2009-03-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/nilotinib-optimal-therapy-for-patients-with-chronic-myeloid-leukemia-a-a3002

Similar Items

Nilotinib therapy in an imatinib intolerant chronic myeloid leukemia patient with pulmonary severe hypertension
by: Mario Annunziata
Published: (2015-10-01)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
by: G Rogers, et al.
Published: (2012-04-01)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

A case of double leukemia: chronic myeloid leukemia intolerant to imatinib and chronic lymphocytic leukemia
by: Miriana Rocchi
Published: (2015-10-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
by: Monika Conchon, et al.
Published: (2011-01-01)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
by: Yoo Jin Na, et al.
Published: (2021-03-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
by: E Loveman, et al.
Published: (2012-05-01)

S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA
by: F. Pane, et al.
Published: (2022-06-01)

Global Longitudinal Strain of Chronic Granulocytic Leukemia Patients treated with Imatinib and Nilotinib
by: Indra Wijaya, et al.
Published: (2021-10-01)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021-11-01)

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
by: Shoumariyeh K, et al.
Published: (2014-09-01)

Development and targeted use of nilotinib in chronic myeloid leukemia
by: Carmen Fava, et al.
Published: (2008-11-01)

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
by: Mario Annunziata
Published: (2015-10-01)

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01)

Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)

Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib
by: Fausto Palmieri
Published: (2015-10-01)

Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report
by: Renato Centrone, et al.
Published: (2020-10-01)

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
by: Soraya Bougherira
Published: (2023-08-01)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
by: Fang Cheng, et al.
Published: (2023-04-01)

Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis
by: Sicong Li, et al.
Published: (2022-11-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
by: Alauldeen Mudhafar Zubair Alqasim, et al.
Published: (2019-01-01)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
by: Vihang Patel, et al.
Published: (2017-05-01)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
by: Shunsuke Maruta, et al.
Published: (2021-08-01)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
by: Piccaluga PP, et al.
Published: (2012-11-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
by: Belinda Pinto Simões, et al.
Published: (2011-02-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy
by: Ayda Bennour, et al.
Published: (2013-03-01)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
by: Yuji Okamoto, et al.
Published: (2022-10-01)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
by: Husam N. Al-Dubai, et al.
Published: (2020-06-01)